Lecanemab in the real world: First UK experience in the new era of disease modifying treatments for Alzheimer’s disease

This report presents the first real-world experience of lecanemab treatment for AD patients in the UK. Our findings demonstrate feasibility of anti-amyloid therapy in clinical practice, manageable safety profile and early indications of positive patient-reported outcomes. These insights can inform service development and support clinical uptake of novel disease-modifying therapies.